Introduction
Sturge-Weber syndrome (SWS) is a neurological disorder that is present at birth. The affected individual has a noticeable distinctive port-wine stain on the forehead, scalp, or around the eye. This stain is a birthmark caused by a blood vessel abnormality. A large number of people with SWS also suffers from seizures or convulsions. Sturge-Weber syndrome develops a blood vessel abnormality called leptomeningeal angiomas in the brain. Other features of this SWS syndrome include glaucoma, paralysis, developmental delay, and intellectual disability. The person suffering from this may also have other complications such as increased pressure in the eye, developmental delays, and weakness on one side of the body. However, the factors responsible for market growth include technological advancements, increasing awareness among people, and increasing government assistance.
However, increasing challenges in research and development, the high cost of treatment, and poor healthcare system may hamper the market growth.
The global sturge-weber syndrome market has been segmented by type, diagnosis and treatment, and end user.
The global sturge-weber syndrome market has been divided, by type into type 1, type 2 and type 3.
Based on diagnosis and treatment, the global sturge-weber syndrome market has been categorized into diagnosis and treatment.
On the basis of end user, the market has been classified as hospitals and clinics and diagnostic centers.
The global sturge-weber syndrome market was valued at USD 2277.4 million in 2017 and is expected to register a CAGR of 5.3 % during the forecast period from 2018 to 2023.
Key Players
Some of the key players in the global sturge-weber syndrome market are Abbott, Pfizer Inc, F. Hoffmann-La Roche AG, Novartis AG, UCB SA, Sanofi, Shire, Aleva Neurotherapeutics SA, GW Pharmaceuticals, PLC, ElectroCore LLC, and Johnson & Johnson.
Objectives of the Study
• To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global sturge-weber syndrome market
• To provide insights into factors influencing and affecting market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global sturge-weber syndrome market
• To provide a detailed analysis of the value chain and supply chain of the global sturge-weber syndrome market
Target Audience
• Potential Investors
• Associations
• Government Research Institutes
• End Users
• Raw Material Suppliers
• Drugs Suppliers and Manufacturers
Key Findings
• The global sturge-weber syndrome market is expected to reach USD 2277.4 million by 2023 at a CAGR of 5.3 % from 2018 to 2023.
• On the basis of type, the type 1 segment accounted for the largest market share of 47.44% in 2017 and is expected to be USD 792.6 million by 2023.
• The market in the Americas is expected to account for the largest share of the global sturge-weber syndrome market and is projected to reach USD 812.2 million by 2023.
• The market in Asia-Pacific is projected to be the fastest growing at a CAGR of 5.9 % from 2018 to 2023.
Regional Analysis
• Americas
o North America
US
Canada
o Latin America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa
Table of Contents:
1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.1 Primary Research
4.2 Secondary Research
4.3 Market Size Estimation
4.4 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 The increasing prevalence of epilepsy and glaucoma
5.2.2 Rising research and development funding for rare diseases
5.2.3 Increasing focus on players towards Sturge-weber syndrome
5.3 Restraints
5.3.1 Side effects of therapeutic drugs
5.4 Opportunities
5.4.1 Rising demand for non-invasive treatment generating requirement for laser therapy
5.5 Macroeconomic Indicators
6 Market Factor Analysis
6.1 Supply Chain Analysis
6.1.1 R&D
6.1.2 Parts Manufacturing
6.1.3 Distribution
6.1.4 Marketing & Sales
6.1.5 Post-Sales Monitoring
6.2 Demand & Supply: Gap Analysis
6.3 Pricing Analysis
6.4 Investment Opportunities
6.5 Porter’s Five Forces Model
6.5.1 Bargaining Power of Suppliers
6.5.2 Bargaining Power of Buyers
6.5.3 Threat of New Entrants
6.5.4 Threat of Substitutes
6.5.5 Intensity of Rivalry
7 Global Sturge-Weber Syndrome Market, by Type
7.1 Overview
7.1.1 Type 1
7.1.2 Type 2
7.1.3 Type 3
8 Global Sturge-Weber Syndrome Market, by Diagnosis & Treatment
8.1 Overview
8.1.1 Treatment
8.1.2 Diagnosis
9 Global Sturge-Weber Syndrome Market, By End-User
9.1 Overview
9.1.1 Hospital & Clinics
9.1.2 Diagnostic Centre
10 Sturge-Weber Syndrome Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East and Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Company Market Share Analysis
11.1.1 Introduction
11.2 Competitive Landscape
11.2.1 Introduction
11.3 Key Developments
12 Company Profiles
12.1 Abbott
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products Offerings
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategy
12.2 Pfizer Inc.
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products Offerings
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.2.6 Key Strategy
12.3 F. Hoffmann-La Roche AG
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products Offerings
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.3.6 Key Strategy
12.4 Novartis AG
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products Offerings
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategy
12.5 UCB S.A.
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products Offerings
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategy
12.6 Sanofi
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products Offerings
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategy
12.7 Shire
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products Offerings
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategy
12.8 Aleva Neurotherapeutics SA
12.8.1 Company Overview
12.8.2 Products Offering
12.8.3 Key Developments
12.8.4 SWOT Analysis
12.8.5 Key Strategy
12.9 GW Pharmaceuticals, plc.
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products Offerings
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategy
12.1 ElectroCore LLC
12.10.1 Company Overview
12.10.2 Products Offerings
12.10.3 Key Developments
12.10.4 SWOT Analysis
12.10.5 Key Strategy
12.11 Johnson & Johnson
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products Offerings
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategy
13 Appendix
13.1 Discussion Blue Print
13.2 References
List of Tables:
TABLE 1 MARKET SYNOPSIS
TABLE 1 PRIMARY INTERVIEWS
TABLE 2 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 1, BY REGION 2015-2023 (USD MILLION)
TABLE 3 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 2, BY REGION 2015-2023 (USD MILLION)
TABLE 4 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 3, BY REGION 2015-2023 (USD MILLION)
TABLE 5 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TREATMENT, BY REGION 2015-2023 (USD MILLION)
TABLE 6 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSIS, BY REGION 2015-2023 (USD MILLION)
TABLE 7 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MEDICATION, BY REGION 2015-2023 (USD MILLION)
TABLE 8 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LASER THERAPY, BY REGION 2015-2023 (USD MILLION)
TABLE 9 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SURGICAL PROCEDURES, BY REGION 2015-2023 (USD MILLION)
TABLE 10 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIEPILEPTIC, BY REGION 2015-2023 (USD MILLION)
TABLE 11 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIGLAUCOMA, BY REGION 2015-2023 (USD MILLION)
TABLE 12 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LATANOPROST, BY REGION 2015-2023 (USD MILLION)
TABLE 13 GLOBAL STURGE-WEBER SYNDROME MARKET FOR BETA-ANTAGONIST EYE DROPS, BY REGION 2015-2023 (USD MILLION)
TABLE 14 GLOBAL STURGE-WEBER SYNDROME MARKET FOR CARBONIC ANHYDRASE INHIBITORS, BY REGION 2015-2023 (USD MILLION)
TABLE 15 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION 2015-2023 (USD MILLION)
TABLE 16 GLOBAL STURGE-WEBER SYNDROME MARKET FOR COMPUTED TOMOGRAPHY (CT) SCAN, BY REGION 2015-2023 (USD MILLION)
TABLE 17 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ELECTROENCEPHALOGRAM (EEG), BY REGION 2015-2023 (USD MILLION)
TABLE 18 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SKULL RADIOGRAPHY, BY REGION 2015-2023 (USD MILLION)
TABLE 19 GLOBAL STURGE-WEBER SYNDROME MARKET FOR HOSPITAL & CLINICS, BY REGION 2015-2023 (USD MILLION)
TABLE 20 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSTIC CENTERS, BY REGION 2015-2023 (USD MILLION)
TABLE 21 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2015-2023 (USD MILLION)
TABLE 22 AMERICAS: STURGE-WEBER SYNDROME MARKET, BY REGION, 2015-2023 (USD MILLION)
TABLE 23 AMERICAS STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 24 AMERICAS STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 25 AMERICAS TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 26 AMERICAS MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 27 AMERICAS ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 28 AMERICAS DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 29 AMERICAS STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 30 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
TABLE 31 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 32 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 33 NORTH AMERICA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 34 NORTH AMERICA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 35 NORTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 36 NORTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 37 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 38 U.S. STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 39 U.S. STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 40 U.S. TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 41 U.S. MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 42 U.S. ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 43 U.S. DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 44 U.S. STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 45 CANADA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 46 CANADA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 47 CANADA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 48 CANADA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 49 CANADA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 50 CANADA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 51 CANADA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 52 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 53 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 54 SOUTH AMERICA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 55 SOUTH AMERICA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 56 SOUTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 57 SOUTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 58 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 59 EUROPE STURGE-WEBER SYNDROME MARKET, BY REGION, 2015-2023 (USD MILLION)
TABLE 60 EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 61 EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 62 EUROPE TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 63 EUROPE MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 64 EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 65 EUROPE DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 66 EUROPE STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 67 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
TABLE 68 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 69 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 70 WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 71 WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 72 WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 73 WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 74 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 75 GERMANY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 76 GERMANY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 77 GERMANY TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 78 GERMANY MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 79 GERMANY ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 80 GERMANY DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 81 GERMANY STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 82 FRANCE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 83 FRANCE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 84 FRANCE TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 85 FRANCE MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 86 FRANCE ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 87 FRANCE DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 88 FRANCE STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 89 U. K STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 90 U. K STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 91 U. K TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 92 U. K MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 93 U. K ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 94 U. K DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 95 U. K STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 96 ITALY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 97 ITALY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 98 ITALY TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 99 ITALY MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 100 ITALY ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 101 ITALY DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 102 ITALY STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 103 SPAIN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 104 SPAIN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 105 SPAIN TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 106 SPAIN MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 107 SPAIN ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 108 SPAIN DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 109 SPAIN STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 110 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 111 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 112 REST OF WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 113 REST OF WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 114 REST OF WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 115 REST OF WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 116 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 117 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 118 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 119 EASTERN EUROPE TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 120 EASTERN EUROPE MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 121 EASTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 122 EASTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 123 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 124 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
TABLE 125 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 126 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 127 ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 128 ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 129 ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 130 ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 131 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 132 JAPAN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 133 JAPAN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 134 JAPAN TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 135 JAPAN MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 136 JAPAN ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 137 JAPAN DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 138 JAPAN STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 139 CHINA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 140 CHINA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 141 CHINA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 142 CHINA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 143 CHINA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 144 CHINA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 145 CHINA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 146 INDIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 147 INDIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 148 INDIA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 149 INDIA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 150 INDIA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 151 INDIA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 152 INDIA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 153 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 154 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 155 AUSTRALIA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 156 AUSTRALIA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 157 AUSTRALIA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 158 AUSTRALIA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 159 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 160 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 161 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 162 REPUBLIC OF KOREA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 163 REPUBLIC OF KOREA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 164 REPUBLIC OF KOREA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 165 REPUBLIC OF KOREA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 166 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 167 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 168 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 174 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY REGION, 2015-2023 (USD MILLION)
TABLE 175 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 176 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 177 MIDDLE EAST AND AFRICA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 178 MIDDLE EAST AND AFRICA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 179 MIDDLE EAST AND AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 180 MIDDLE EAST AND AFRICA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 181 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 182 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 183 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 184 MIDDLE EAST TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 185 MIDDLE EAST MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 186 MIDDLE EAST ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 187 MIDDLE EAST DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 188 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 189 AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 190 AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2015-2023 (USD MILLION)
TABLE 191 AFRICA TREATMENT MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 192 AFRICA MEDICATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 193 AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 194 AFRICA DIAGNOSIS MARKET, BY TYPE, 2015-2023 (USD MILLION)
TABLE 195 AFRICA STURGE-WEBER SYNDROME MARKET, BY END USER, 2015-2023 (USD MILLION)
TABLE 196 GLOBAL STURGE-WEBER SYNDROME MARKET: KEY DEVELOPMENT
List of Figures:
FIGURE 1 GLOBAL STURGE-WEBER SYNDROME MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS OF MRFR
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4 MARKET DYNAMICS ANALYSIS OF GLOBAL STURGE-WEBER SYNDROME MARKET
FIGURE 5 SUPPLY CHAIN: STURGE-WEBER SYNDROME MARKET
FIGURE 6 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL STURGE-WEBER SYNDROME MARKET
FIGURE 7 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2017 (% SHARE)
FIGURE 8 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2017 & 2023 (USD MILLION)
FIGURE 9 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2017 (% SHARE)
FIGURE 10 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2017 & 2023 (USD MILLION)
FIGURE 11 GLOBAL STURGE-WEBER SYNDROME MARKET, BY END USER, 2017 (% SHARE)
FIGURE 12 GLOBAL STURGE-WEBER SYNDROME MARKET, BY APPLICATION, 2017 & 2023 (USD MILLION)
FIGURE 13 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2017 & 2023 (USD MILLION)
FIGURE 14 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2017 (% SHARE)
FIGURE 15 AMERICAS: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2017 (%)
FIGURE 16 EUROPE: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2017 (%)
FIGURE 17 ASIA PACIFIC: STURGE-WEBER SYNDROME MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 18 THE MIDDLE EAST AND AFRICA: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2017 (%)
FIGURE 19 GLOBAL STURGE-WEBER SYNDROME MARKET, MARKET SHARE ANALYSIS 2017 (%)
FIGURE 20 GLOBAL STURGE-WEBER SYNDROME MARKET: COMPETITIVE LANDSCAPE 2017 (%)
12.1 Abbott
12.2 Pfizer Inc.
12.3 F. Hoffmann-La Roche AG
12.4 Novartis AG
12.5 UCB S.A.
12.6 Sanofi
12.7 Shire
12.8 Aleva Neurotherapeutics SA
12.9 GW Pharmaceuticals, plc.
12.10 ElectroCore LLC
12.11 Johnson & Johnson
